Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.
Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.
The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.
There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.
The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.
This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.
Student loan borrowers have the ability to earn retirement funds pegged to their payments – and the company Summer might be bringing it to your workplace.
It might not be what investors want to hear… but bringing down inflation could mean interest rates stay higher for (even) longer. But it's not all downside.
President Joe Biden and Chinese President Xi Jinping have discussed Taiwan, artificial intelligence and security issues in a call meant to demonstrate a return to regular leader-to-leader dialogue between the two powers.
April is Earth month, and while the green revolution might feel far away, the founder of climate VC Siam Capital says it’s on it’s way, and, even better: it won't cost you more.
From snow in April to heatwaves in December, it’s hard to plan a trip in a climate change world. Startup Sensible Weather thinks weather-based travel reimbursements are the solution.
Between corporate debt and the widening gap between ‘the haves and the have nots,’ there are reasons to be cautious about the economy, even with interest rate cuts on their way.
If the A.I. hype hasn’t given you enough of a reason to be excited (and a little terrified), the CEO of Zapata AI says the next frontier is designing bridges or creating pharmaceutical drugs.
